Hyperuricemia and tuberculosis
- Authors: Komissarova O.G1,2, Abdullaev R.Y.1, Aleshina S.V1
-
Affiliations:
- Central Research Institute of Tuberculosis
- N.I. Pirogov Russian National Research Medical University
- Issue: Vol 31, No 11 (2020)
- Pages: 5-9
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114317
- DOI: https://doi.org/10.29296/25877305-2020-11-01
- ID: 114317
Cite item
Abstract
The paper provides an update on the mechanism of hyperuricemia, its impact on different organs and systems. It analyzes the data available in the literature on the frequency and characteristics of hyperuricemia in patients with tuberculosis both before the start of treatment and during therapy. The paper also highlights the potential complications of prolonged hyperuricemia and approaches to its combination treatment for pulmonary tuberculosis.
Keywords
Full Text
About the authors
O. G Komissarova
Central Research Institute of Tuberculosis; N.I. Pirogov Russian National Research Medical University
Email: rizvan0403@yandex.ru
MD Moscow
R. Yu Abdullaev
Central Research Institute of Tuberculosis
Email: rizvan0403@yandex.ru
MD Moscow
S. V Aleshina
Central Research Institute of Tuberculosis
Email: rizvan0403@yandex.ru
Moscow
References
- Абдуллаев Р.Ю., Комиссарова О.Г., Чумакова Е.С. и др. Уровень мочевой кислоты в сыворотке крови у больных впервые выявленным туберкулезом легких с множественной лекарственной устойчивостью возбудителя. Туберкулез и болезни легких. 2017; 95 (4): 31-6 https://doi.org/10.21292/2075-1230-2017-95-4-31-36
- Елисеева М.Е., Елисеев М.С. Гиперурикемия как фактор риска развития патологии почек и перспективы уратснижающей терапии. Эффективная фармакотерапия. 2019; 15 (23): 26-30 https://doi.org/10.33978/2307-3586-2019-15-23-26-30
- Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего проспективного наблюдения). Тер арх. 2015; 87 (5): 10-5. https://ter-arkhiv.ru/0040-3660/article/view/31721
- Иванова Д.А., Борисов С.Е., Рыжов А.М. Гиперурикемия при лечении больных туберкулезом: клиническое значение, факторы риска, принципы мониторинга. Туберкулез и социально-значимые заболевания. 2017; 3: 24-31
- Мадянов И.В. Гиперурикемия и сахарный диабет. РМЖ. Медицинское обозрение. 2019; 1 (I): 20-4
- Рамеев В.В., Елисеев М.С., Моисеев С.В. Концепция аутовоспаления в генезе подагры и гиперурикемии. Клиническая фармакология и терапия. 2019; 28 (2): 28-33 https://doi.org/10.32756/0869-5490-2019-2-28-33
- Федеральные клинические рекомендации по диагностике и лечению туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью возбудителя. М.; Тверь: ООО «Издательство «Триада», 2014; 72 с.
- Adebisi S.A., Oluboyo P.O., Okesina A.B. Effect of drug-induced hyperuricaemia on renal function in Nigerians with pulmonary tuberculosis. Afr J Med Med Sci. 2000; 29 (3-4): 297-300.
- Benn C.L., Dua P., Gurrell R. et al. Physiology of hyperuricemia and uratelowering treatments. Front Med (Lausanne). 2018; 5: 160. doi: 10.3389/fmed.2018.00160
- Pokam B.D.T., Enoh J. et al. Uric acid levels in patients on antituberculosis drugs in the Southwest region of Cameroon. Int J Mycobacteriol. 2016; 5 (Suppl. 1): S116. doi: 10.1016/j.ijmyco.2016.09.058
- Chang H.Y., Lee P.H., Lei C.C. et al. Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in Taiwan. PLoS One. 2013; 8 (4): e61450. doi: 10.1371/journal.pone.0061450
- Gerdan V., Akkoc N., Ucan E. S. et al. Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia. Singapore Med J. 2013; 54: 125-6. doi: 10.11622/smedj.2013097
- Cheong, E., Ryu S., Lee J.Y. Association between serum uric acid and cardiovascular mortality and all-cause mortality: a cohort study. J Hypertens. 2017; 35 (Suppl. 1): S3-S9. doi: 10.1097/HJH.0000000000001330
- Gibbs B.F., Gonçalves Silva I., Prokhorov A. et al. Caffeine affects the biological responses of human hematopoietic cells of myeloid lineage via downregulation of the mTOR pathway and xanthine oxidase activity. Oncotarget. 2015; 6 (30): 28678-92. doi: 10.18632/oncotarget.5212
- Gutman A.B., Yu T.F., Berger L. Renal function in gout. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid). Am J Med. 1969; 47 (4): 575-92. doi: 10.1016/0002-9343(69)90188-0
- Harris A., Siegel L., Alloway J. Gout and hyperuricemia. Am Fam Phys. 1999; 59 (4): 925-34.
- Hayashino Y., Okamura S., Tsujii S. et al. Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study. Acta Diabetologica. 2016; 53 (4): 599-607. doi: 10.1007/s00592-015-0825-x
- Horsfall P.A., Plummer J., Allan W.G. et al. Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. Tubercle. 1979; 60: 13-24. doi: 10.1016/0041-3879(79)90051-5
- Hsieh Y.P., Chang C.C., Yang Y. et al. The role of uric acid in chronic kidney disease patients. Nephrology (Carlton). 2017; 22 (6): 441-8. doi: 10.1111/nep.12679
- Inayat N., Shah R.H., Lakhair M.A. et al. Hyperuricemia and arthralgia during pyrazinamide therapy in patients with pulmonary tuberculosis. Pak J Chest Med. 2016; 22 (4): 154-8.
- Inoue T., Ikeda N., Kurasawa T. et al. Hyperuricemia and arthralgia during pyrazinamide treatment. Nihon Kokyuki Gakkai Zasshi. 1999; 37: 115-8.
- Joosten L.A.B., Crişan T.O., Bjornstad P. et al. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev.Rheumatol. 2020; 16 (2): 75-86. https://doi.org/10.1038/s41584-019-0334-3
- Kim Y., Kang J., Kim G.T. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 2018; 37: 2529-38. doi: 10.1007/s10067-018-4130-2
- Lacroix C., Guyonnaud C., Chaou M. et al. Interaction between allopurinol and pyrazinamide. Eur Respir J. 1988; 1: 807-11.
- Liu Y., Yan L., Lu J. et al. A pilot study on the epidemiology of hyperuricemia in Chinese adult population based on big data from Electronic Medical Records 2014 to 2018. Minerva Endocrinol. 2020; 45 (2): 97-105. https://doi.org/10.23736/ S0391-1977.20.03131-4
- Louthrenoo W., Hongsongkiat S., Kasitanon N. et al. Effect of Antituberculous Drugs on Serum Uric Acid and Urine Uric Acid Excretion. J Clin Rheumatol. 2015; 21 (7): 346-8. doi: 10.1097/RHU.0000000000000297
- Lu J., He Y., Cui L. et al. Hyperuricemia Predisposes to the Onset of Diabetes via Promoting Pancreatic ß-Cell Death in Uricase Deficiency Male Mice. Diabetes. 2020; 69 (6): 1149-63. https://doi.org/10.2337/db19-0704
- Mahantesh A., Hanumantharayappa B., Madhava R.P. et al. Effect of pyrazinamide induced hyperuricemia on patient compliance undergoing DOTS therapy for tuberculosis. RRJPTS. 2014; 2 (2): 12-8.
- Maloberti A., Giannattasio C., Bombelli M. et al. Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020; 27 (2): 1218. https://doi. org/ 10.1007/s40292-020-00368-z
- Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018; 484: 150-63. doi: 10.1016/j.cca.2018.05.046
- Park R., Kang M.G. Association Between Serum Uric Acid and Prediabetes in the Korean General Population. Asia Pac J Public Health. 2019; 31 (8): 719-27. https://doi.org/10.1177/1010539519886705
- Pichholiya M., Yadav A.K., Luhadia S.K. et al. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients. Indian J Pharmacol. 2016; 48 (5): 522-5. doi: 10.4103/0253-7613.190729
- Pichholiya, M., Yadav A.K., Kothari N. Effect of diet, body mass index, and proton pump inhibitors on antitubercular therapy-induced hyperuricemia in patients of tuberculosis. Natl J Physiol Pharm Pharmacol. 2016; 6 (2):158-61. doi: 10.5455/njppp.2016.6.1412201510
- Pillai A.P., Maldhure B.R., Zodpey S.P. Hyperuricemia during antituberculous treatment. Lung India. 1998; 17: 19-22.
- Postlethwaite A.E., Bartel A.G., Kelley W.N. Hyperuricemia due to ethambutol. N Engl J Med. 1972; 286: 761-2. doi: 10.1056/NEJM197204062861407
- Qureshi W., Hassan G., Kadri S.M. et al. Hyperuricemia and arthralgias during pyrazinamide therapy in patients with pulmonary tuberculosis. Lab Med. 2007; 38: 495-7.
- Rafiullah M., Siddiqui K., Al-Rubeaan K. Association between serum uric acid levels and metabolic markers in patients with type 2 diabetes from a community with high diabetes prevalence. Int J Clin Pract. 2020; 74 (4): e13466. https://doi.org/10.1111/ijcp.13466
- Sedaghat S., Hoorn E.J., van Rooij F.J. et al. Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One. 2013; 8 (11): e76827. doi: 10.1371/journal.pone.0076827
- Sismanlar T., Aslan A.T., Budakoglu I. Is hyperuricemia overlooked when treating pediatric tuberculosis patients with pyrazinamide? J Trop Pediatr. 2015; 61: 351-6. doi: 10.1093/tropej/fmv042
- Solangi G.A., Zuberi B.F., Shaikh S. et al. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. J Coll Physicians Surg Pak. 2004; 14 (3): 136-8.
- Taki H., Ogawa K., Murakami T. et al. Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. Kekkaku. 2008; 83: 497-501.
- Tosun A.K., Koca N.T., Karataş G.K. Acute gouty arthritis during pyrazinamide treatment: a case report. Mod Rheumatol. 2004; 14 (4): 306-8.
- Wang J., Pang Yu., Jing W. et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist. 2019; 12: 763-70. doi: 10.2147/IDR.S194484
- Woldeamlak B., Yirdaw K., Biadgo B. Hyperuricemia and its Association with Cardiovascular Disease Risk Factors in Type Two Diabetes Mellitus Patients at the University of Gondar Hospital, Northwest Ethiopia. EJIFCC. 2019; 30 (3): 325-39.
- Zhou Y., Fang L., Jiang L. et al. Uric acid induces renal inflammation via activating tubular NF-kB signaling pathway. PLoS One. 2012; 7 (6): e39738. https://doi.org/10.1371/journal.pone.0039738
- Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63: 3136-41. doi: 10.1002/art.30520